There is no correlation between the antitumour activity of gefitinib and EGFR expression level; however, recent research revealed that gefitinib-responsive lung cancers harbour somatic mutations within the EGFR kinase domain (Lynch et al, 2004; Paez et al, 2004; Sordella et al, 2004). This evidence concerns the gene EGFR and lung cancer.